340B Drug Pricing Program Contributes to Rising Healthcare Costs and Is Ripe for Reform
The U.S. House Energy & Commerce Committee's Health Subcommittee today will host the third hearing in its health care affordability series, specifically examining the role providers and hospitals play in shaping the cost of care for Americans.
While the hearing will likely examine numerous issues, there is none more ripe for reform than the flawed 340B drug pricing program.
Originally enacted to help eligible safety-net providers buy medicines at steep discounts and pass the savings on to lower-income and vulnerable patients, the program has ballooned as a revenue stream for many participating hospitals and contract pharmacy chains.
As the size and complexity of the 340B program has expanded, participating hospitals and contract pharmacies have instead used the program to increase…[more]
With the geniuses we have in Congress, no problem should be too tough to solve, whether it's inflation, health care costs, war or disease.
Ten members ended 2025 with stock market returns far exceeding the S&P, the Dow, the Nasdaq or what legendary stock pickers like Warren Buffet achieve. Rep. Tim Moore (R-N.C.) earned 52% on his stock portfolio; New York's Tom Suozzi (D), representing parts of Queens and the Long Island "gold coast," scored a 35% gain. Rep. Marjorie Taylor Greene is closing out her Congressional career with a staggering 33% stock profit for 2025.
Unfortunately…
